Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of the American Society of Nephrology

• Publication date

  2009-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1681/ASN.2009070737PMID 19926893PMCID PMC2794224
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Aldosterone blockade in diabetic nephropathy: relative risks and potential promise.

  2009cited by this paper
• Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review.

  2008cited by this paper
• Aldosterone and glomerular podocyte injury

  2008cited by this paper
• Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

  2008cited by this paper
• The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology

  2007cited by this paper
• Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function

  2006cited by this paper
• Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker.

  2006cited by this paper
• Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy.

  2006cited by this paper
• Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.

  2006cited by this paper
• Aldosterone antagonism in chronic kidney disease.

  2006cited by this paper
• Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study.

  2006cited by this paper
• Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.

  2005cited by this paper
• Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial.

  2005cited by this paper
• Proteinuria reduction: Mandatory consideration or option when selecting an antihypertensive agent?

  2005cited by this paper
• Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study.

  2005cited by this paper
• Effect of aldosterone on renal transforming growth factor-beta.

  2004cited by this paper
• Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization.

  2004cited by this paper
• K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease

  2004cited by this paper
• Aldosterone Antagonism Ameliorates Proteinuria and Nephrosclerosis Independent of Glomerular Dynamics in L-NAME/SHR Model

  2004cited by this paper
• K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease.

  2004cited by this paper
• The JNC 7 Approach Compared to Conventional Treatment in Diabetic Patients With Hypertension: A Double‐Blind Trial of Initial Monotherapy vs. Combination Therapy

  2004cited by this paper
• Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

  2004cited by this paper
• Aldosterone in the development and progression of renal injury.

  2004cited by this paper
• The EPHESUS Trial: Eplerenone in Patients with Heart Failure Due to Systolic Dysfunction Complicating Acute Myocardial Infarction

  2004cited by this paper
• Diabetic nephropathy: Linking histology, cell biology, and genetics.

  2004cited by this paper
• Aldosterone receptor blockade and the role of eplerenone: evolving perspectives.

  2003cited by this paper
• The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

  2003cited by this paper
• Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

  2003cited by this paper
• Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy

  2003cited by this paper
• Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

  2003cited by this paper
• Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

  2001cited by this paper
• Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

  2001cited by this paper
• Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.

  2000cited by this paper
• The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

  2000cited by this paper
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999cited by this paper
• Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group.

  1999cited by this paper
• Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.

  1998cited by this paper
• Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)

  1997cited by this paper
• Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

  1997cited by this paper
• Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment

  1994cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.

  1994cited by this paper
• Impact of Arterial Blood Pressure and Albuminuria on the Progression of Diabetic Nephropathy in IDDM Patients

  1993cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.

  1993cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.

  1993cited by this paper
• Prognosis in diabetic nephropathy.

  1989cited by this paper
• Prognosis in diabetic nephropathy.

  1989cited by this paper
• A method for estimating nitrogen intake of patients with chronic renal failure.

  1985cited by this paper
• Downloaded from http://hyper.ahajournals.org / by guest on February 21, 2013Role of Aldosterone in Renal Vascular Injury in Stroke-Prone Hypertensive Rats

  year unknowncited by this paper

• 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026.

  2025cites this paper
• Real-world use of finerenone in diabetic kidney disease: eGFR slope analysis with exploratory data on prior MRA use

  2025cites this paper
• Spironolactone protects against hypertension-induced renal fibrosis by promoting autophagy and inhibiting the NLRP3 inflammasome

  2025cites this paper
• Comparative Efficacy and Safety of Finerenone, Eplerenone, and Spironolactone on Cardiorenal Outcomes in Type 2 Diabetes with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis

  2025cites this paper
• Use of finerenone in patients with chronic kidney disease at high risk of heart failure.

  2025cites this paper
• Urinary cortisol-to-cortisone ratio levels modify the association between diabetes and hypertension: a cross-sectional study of 6931 older adults

  2025cites this paper
• Effect of spironolactone on cardiovascular and renal outcomes in patients with chronic kidney disease

  2025cites this paper
• Cardiovascular risk reduction in type 2 diabetes: What the non‐specialist needs to know about current guidelines

  2024cites this paper
• New ways of mitigating aldosterone in cardiorenal disease.

  2024cites this paper
• Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials.

  2024cites this paper
• Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease: Clinical Evidence and Potential Adverse Events

  2024cites this paper
• Association between mineralocorticoid receptor antagonists and kidney harm: A systematic review and meta‐analysis of randomized controlled trials

  2024cites this paper
• Renin-Angiotensin-Aldosterone System Modulators in Adults with Hypertension: A Network Meta-Analysis of Randomized Controlled Trials

  2024cites this paper
• Management of Hypertension in Patients with Type 2 Diabetes Mellitus: Indian Guideline 2024 by Association of Physicians of India and Indian College of Physicians.

  2024influential citation
• Mineralocorticoid receptor overactivation in diabetes mellitus: role of O-GlcNAc modification

  2024cites this paper
• Efficacy and safety of nonsteroidal mineralocorticoid receptor antagonists for renal and cardiovascular outcomes in patients with chronic kidney disease: a meta-analysis of randomized clinical trials

  2024cites this paper
• Alport Syndrome.

  2024cites this paper
• Finerenone: From the Mechanism of Action to Clinical Use in Kidney Disease

  2024cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2025.

  2024cites this paper
• Leptin in reproduction and hypertension in pregnancy.

  2024cites this paper
• Pharmacological Nephroprotection in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus—Clinical Practice Position Statement of the Polish Society of Nephrology

  2024cites this paper
• A European Renal Association (ERA) synopsis for nephrology practice of the 2023 European Society of Hypertension (ESH) Guidelines for the Management of Arterial Hypertension

  2024cites this paper
• Retrospective evaluation of patients diagnosed with Primary Hyperaldosteronism

  2024cites this paper
• Treatment and practical considerations of diabetic kidney disease

  2023cites this paper
• Clinical outcomes of renin angiotensin system inhibitor-based dual antihypertensive regimens in chronic kidney disease: a network meta-analysis

  2023cites this paper
• Néphropathie diabétique

  2023cites this paper
• Neue Leitlinien der European Society of Hypertension

  2023cites this paper
• Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial

  2023cites this paper
• Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA)

  2023cites this paper
• Mineralocorticoid Receptor Antagonists for Preventing Chronic Kidney Disease Progression: Current Evidence and Future Challenges

  2023cites this paper
• Mineralocorticoid receptor antagonism in diabetes reduces albuminuria by preserving the glomerular endothelial glycocalyx

  2023influential citation
• Efficacy and safety assessment of mineralocorticoid receptor antagonists in patients with chronic kidney disease.

  2023cites this paper
• 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH).

  2023cites this paper
• Non‐steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes

  2023cites this paper
• Proteinuria and Renal Dysfunction Due to Extremely Low Birth Weight in a Patient with Silver-Russell Syndrome.

  2023cites this paper
• The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis

  2023cites this paper
• Finerenone: Questions and Answers—The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist

  2023cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024.

  2023cites this paper
• Effect of Sequential Nephron Blockade versus Dual Renin-Angiotensin System Blockade Plus Bisoprolol in the Treatment of Resistant Hypertension, a Randomized Controlled Trial (Resistant Hypertension on Treatment - ResHypOT)

  2022cites this paper
• Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: a systematic review and network meta-analysis.

  2022cites this paper
• Mechanisms of mineralocorticoid receptor-associated hypertension in diabetes mellitus: the role of O-GlcNAc modification

  2022cites this paper
• KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.

  2022cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023.

  2022cites this paper
• Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial

  2022cites this paper
• Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria

  2022cites this paper
• Effects of sodium‐glucose cotransporter‐2 inhibitors and aldosterone antagonists, in addition to renin‐angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta‐analysis

  2022cites this paper
• Mineralocorticoid receptor antagonists for cardioprotection in chronic kidney disease: a step into the future

  2022cites this paper
• Role of Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease

  2022cites this paper
• The 2021–2022 position of Brazilian Diabetes Society on diabetic kidney disease (DKD) management: an evidence-based guideline to clinical practice. Screening and treatment of hyperglycemia, arterial hypertension, and dyslipidemia in the patient with DKD

  2022cites this paper
• Mineralocorticoid Receptor Antagonist Use and Hard Renal Outcomes in Real-World Patients With Chronic Kidney Disease

  2022cites this paper
• Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists

  2022cites this paper
• Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease

  2022cites this paper
• Hypertension and Type 2 Diabetes—The Novel Treatment Possibilities

  2022influential citation
• Effect of Sequential Nephron Blockade versus Dual Renin-Angiotensin System Blockade Plus Bisoprolol in the Treatment of Resistant Hypertension, a Randomized Controlled Trial (Resistant Hypertension on Treatment - ResHypOT)

  2022cites this paper
• Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease

  2021cites this paper
• Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment

  2021cites this paper
• Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study

  2021cites this paper
• Evaluation of symmetric dimethylarginine and creatinine in dogs with primary hypoadrenocorticism receiving long-term mineralocorticoid replacement therapy.

  2021cites this paper
• Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease.

  2021cites this paper
• Efficacy and Safety of Angiotensin-Converting Enzyme Inhibitor in Combination with Angiotensin-Receptor Blocker in Chronic Kidney Disease Based on Dose: A Systematic Review and Meta-Analysis

  2021cites this paper
• Decision Points in the Management of Patients with Diabetic Kidney Disease.

  2021cites this paper
• KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.

  2021cites this paper
• Diabetic kidney disease in type 2 diabetes: a review of pathogenic mechanisms, patient-related factors and therapeutic options

  2021cites this paper
• Mineralocorticoid receptor antagonists in diabetic kidney disease — mechanistic and therapeutic effects

  2021cites this paper
• Mineralcorticoid receptor blockers in chronic kidney disease.

  2021cites this paper
• Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease

  2021cites this paper
• Efficacy and safety of dual vs single renin–angiotensin–aldosterone system blockade in chronic kidney disease

  2021cites this paper
• Hyperkalemia with RAAS Inhibition: Mechanism, Clinical Significance, and Management.

  2021cites this paper
• The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists

  2021cites this paper
• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.

  2020cites this paper
• Type 2 Cardiorenal Syndrome

  2020cites this paper
• Mineralcorticoid receptor blockers in chronic kidney disease.

  2020cites this paper
• Comparative risk of new‐onset hyperkalemia for antihypertensive drugs in patients with diabetic nephropathy: A Bayesian network meta‐analysis

  2020cites this paper
• KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.

  2020cites this paper
• Mineralocorticoid receptor antagonists in patients with chronic kidney disease.

  2020cites this paper
• Nuclear receptors in podocyte biology and glomerular disease

  2020cites this paper
• Diabetic Kidney Disease.

  2020cites this paper
• Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension

  2020cites this paper
• Approach to Chronic Kidney Disease in the Diabetic Patient

  2020cites this paper
• Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.

  2020cites this paper
• Non‐steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease

  2020cites this paper
• Baseline urinary metabolites predict albuminuria response to spironolactone in type 2 diabetes.

  2020cites this paper
• Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone

  2020cites this paper
• Use of Diuretics in Chronic Kidney Disease Patients

  2020cites this paper
• New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure

  2019cites this paper
• Mineralocorticoid Receptor Antagonists in Cardiovascular Medicine: Looking for the Forest Among the Trees.

  2019cites this paper
• Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study

  2019cites this paper
• The endogenous cardiotonic steroid Marinobufagenin and decline in estimated glomerular filtration rate at follow-up in patients with arterial hypertension

  2019cites this paper
• Mineralocorticoid Receptor Antagonists in Essential and Resistant Hypertension.

  2019cites this paper
• Efficacy and Safety of Dual Blockade of the Renin–Angiotensin–Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis

  2019cites this paper
• A Dose Response Analysis of Dual Renin Angiotensin Aldosterone System (RAAS) Blockade Among Diabetic Nephropathy Patients with Albuminuria and Proteinuria: A Meta-Analysis

  2019cites this paper
• Boosting the Limited Use of Mineralocorticoid Receptor Antagonists Through New Agents for Hyperkalemia.

  2019cites this paper
• Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials.

  2019cites this paper
• Chaperone co‐inducer BGP‐15 mitigates early contractile dysfunction of the soleus muscle in a rat ICU model

  2019cites this paper
• Microalbuminuria and cardiorenal risk: old and new evidence in different populations

  2019cites this paper
• Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial

  2019cites this paper
• Diuretics

  2019cites this paper
• Large-Artery Stiffness in Health and Disease: JACC State-of-the-Art Review.

  2019cites this paper
• Mineralocorticoid receptor blockade suppresses dietary salt-induced ACEI/ARB-resistant albuminuria in non-diabetic hypertension: a sub-analysis of evaluate study

  2019cites this paper
• Mineralocorticoid Receptor Antagonists for Nephroprotection: Current Evidence and Future Perspectives.

  2019cites this paper